Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53

Cancer Gene Therapy

Volumn 8, Issue 2, 2001, Pages 87-98

  Odin, Laurence ^a   Favrot, Marie ^a   Poujol, Dominique ^a   Michot, Jean Philippe ^a   Moingeon, Philippe ^b   Tartaglia, James ^c   Puisieux, Isabelle ^a  

^a CENTRE LÉON BÉRARD   (France)

^b Pasteur Merieux Connaught Grp   (France)

^c Virogenetics Inc   (United States)

Author keywords

ALVAC; Canarypox virus; Gene therapy; p53

Indexed keywords

PROTEIN P21; PROTEIN P53; TUMOR ANTIGEN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; IMMUNE RESPONSE; IMMUNOGENICITY; LUNG METASTASIS; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; TUMOR REGRESSION; VIRUS RECOMBINANT;

ANIMALIA; CANARYPOX VIRUS; MURINAE; POXVIRIDAE;

EID: 0035103277     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700279     Document Type: Article

References (35)

1. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
2. p53 mutations in human cancers
3. The p53 proto-oncogene can act as a suppressor of transformation
4. p53-oriented cancer therapies: Current progress
5. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
6. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model
7. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53)
8. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
9. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer
10. Parental gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity
11. The p53 tumor suppressor gene
12. Primary proliferative T-cell response to wild-type p53 protein in patients with breast cancer
13. In vitro induction of human cytotoxic T-lymphocyte responses against peptides of mutant and wild-type p53
14. Spontaneous squamous cell carcinomas are killed by a human cytotoxic T-lymphocyte clone recognizing a wild-type p53-derived peptide
15. Human tumor antigens recognized by T lymphocytes
16. Applications of pox virus vectors to vaccination: An update
17. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: An alternative poxvirus vector system
18. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen
19. TS/A: A new metastasizing cell line originated from balb-c spontaneous mammary adenocarcinoma
20. Cell surface antigens of chemically induced sarcomas of the mouse: I. Murine leukemia virus related antigens and alloantigens on culture fibroblasts and sarcomas: Description of a unique antigen on BALB/c Meth A sarcoma
21. NYVAC: A highly attenuated strain of vaccinia virus
22. Highly attenuated poxvirus vectors
23. Cloning and expression of foreign genes in vaccinia virus using a host range selection system
24. The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity
25. Canarypox virus-mediated IL12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long term antitumoral immunity
26. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors
27. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines
28. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
29. Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model
30. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses
31. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to mutational hot spot
32. Structural aspects of the p53 protein in relation to gene evolution
33. p53 as a target for cancer vaccines: Recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge
34. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes
35. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin-12 (IL12) or other cytokines compared with exogenous IL12